Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin: Toxicity, dosimetry, and therapeutic response

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 5, 2011, Pages 603-614

  Soundararajan, Anuradha ^a   Bao, Ande ^a   Phillips, William T ^a   McManus, Linda M ^b   Goins, Beth A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

186Re; head and neck cancer; imaging; liposomal doxorubicin; MTD; radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN RE 186; LIPOSOME; MACROGOL RE 186; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; RADIOISOTOPE; RHENIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DOSIMETRY; DRUG EFFICACY; HEAD AND NECK TUMOR; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; RAT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DRUG SCREENING; HUMAN; MULTIMODALITY CANCER THERAPY; NUDE RAT; RADIOMETRY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEAD AND NECK NEOPLASMS; HUMANS; MALE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; RHENIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054701371     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0948     Document Type: Article

References (70)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153.
2. Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control 2002; 9:387.
3. Dennington ML, Carter DR, Meyers AD. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope 1980;90:196.
4. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993;328:184.
5. Zbaren P, Lehmann W. Frequency and sites of distant me-tastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 1987;113:762.
6. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583.
7. Vokes E. Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol 2005;16 Suppl 6:vi25.
8. Brizel DM. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol 1998;8:237.
9. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95.
10. Mitra A, Nan A, Line BR, Ghandehari H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 2006;12:4729.
11. Lasic DD. Novel applications of liposomes. Trends Bio-technol 1998;16:307.
12. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145.
13. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007;9:E128.
14. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42:419.
15. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424.
16. Faivre S, Alsabe H, Djafari L, et al. Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: A phase I-II study in patients with recurrent squa-mous cell carcinoma of the head and neck. Eur J Cancer 2004;40:1517.
17. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pe-gylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 2000;6:4939.
18. Carlsson J, Forssell Aronsson E, Hietala SO, et al. Tumour therapy with radionuclides: Assessment of progress and problems. Radiother Oncol 2003;66:107.
19. Hamoudeh M, Kamleh MA, Diab R, et al. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008;60:1329.
20. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996;41:1905.
21. Borjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003;9(10 Pt 2):3961S.
22. Colnot DR, Quak JJ, Roos JC, et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999.
23. Postema EJ, Borjesson PK, Buijs WC, et al. Dosimetric analysis of radioimmunotherapy with 186Re-labeled biva-tuzumab in patients with head and neck cancer. J Nucl Med 2003;44:1690.
24. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: An overview. Int J Radiat Oncol Biol Phys 2006;66(2 Suppl):S89.
25. Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med 2001;31:330.
26. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic do-simetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001;42:499.
27. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: Toward liposome-targeted therapeutic radiopharmaceuti-cals. Anticancer Res 2000;20:3339.
28. Liu CM, Chang CH, Chang YJ, et al. Preliminary evaluation of acute toxicity of (188) Re-BMEDA-liposome in rats. J Appl Toxicol 2010;30:680.
29. Chang YJ, Chang CH, Chang TJ, et al. Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007;27:2217.
30. Chang YJ, Chang CH, Yu CY, et al. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol 2010;37:95.
31. Chen LC, Chang CH, Yu CY, et al. Biodistribution, pharma-cokinetics and imaging of (188)Re-BMEDA-labeled pegy-lated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007;34:415.
32. Chen MH, Chang CH, Chang YJ, et al. MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res 2010;30:65.
33. Bao A, Goins B, Klipper R, et al. 186Re-liposome labeling using 186Re-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44:1992.
34. Bao A, Goins B, Klipper R, et al. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacoki-netic and non-invasive imaging studies. J Pharmacol Exp Ther 2004;308:419.
35. Soundararajan A, Bao A, Phillips WT, et al. [(186)Re]-Liposomal doxorubicin (Doxil): In vitro stability, pharma-cokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol 2009;36:515.
36. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989;81:1484.
37. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980;104:10.
38. Shimada K, Matsuo S, Sadzuka Y, et al. Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int J Pharm 2000;203:255.
39. Bao A, Phillips WT, Goins B, et al. Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. Otolaryngol Head Neck Surg 2006;135:853.
40. Vrekoussis T, Chaniotis V, Navrozoglou I, et al. Image analysis of breast cancer immunohistochemistry-stained sections using Image J: An RGB-based model. Anticancer Res 2009;29:4995.
41. Funk T, Sun M, Hasegawa BH. Radiation dose estimate in small animal SPECT and PET. Med Phys 2004;31:2680.
42. Bao A, Zhao X, Phillips WT, et al. Theoretical study of the influence of a heterogeneous activity distribution on in-tratumoral absorbed dose distribution. Med Phys 2005; 32:200.
43. Prestwich WV, Nunes J, Kwok CS. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989;30:1036.
44. Simpkin DJ, Mackie TR. EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 1990;17:179.
45. Kievit E, van Gog FB, Schluper HM, et al. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Int J Radiat Oncol Biol Phys 1997;38:813.
46. Wang SX, Bao A, Herrera SJ, et al. Intraoperative 186Re-liposome radionuclide therapy in a head and neck squa-mous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 2008;14:3975.
47. Gerretsen M, Visser GW, Brakenhoff RH, et al. Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48. Cell Biophys 1994; 24-25:135.
48. Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: Effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986;27:422.
49. Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: Current status and future prospects. J Drug Target 2002;10:535.
50. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008;5:25.
51. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73.
52. Aytac U, Claret FX, Ho L, et al. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 2001;61:7204.
53. Ling YH, el-Naggar AK, Priebe W, et al. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996;49:832.
54. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 1999;9(2 Suppl 1):12.
55. Fornari FA, Jr., Jarvis WD, Grant S, et al. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubi-cin. Cell Growth Differ 1994;5:723.
56. Fornari FA, Randolph JK, Yalowich JC, et al. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649.
57. Supiot S, Gouard S, Charrier J, et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005;11(19 Pt 2):7047s.
58. Chatal JF, Saccavini JC, Gestin JF, et al. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperi-toneally injected into patients operated on for ovarian carcinomas. Cancer Res 1989;49:3087.
59. Bao A, Phillips WT, Goins B, et al. Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection. Int J Pharm 2006;316:162.
60. French JT, Goins B, Saenz M, et al. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol 2010;21:1271.
61. Mulrane L, Rexhepaj E, Penney S, et al. Automated image analysis in histopathology: A valuable tool in medical diagnostics. Expert Rev Mol Diagn 2008;8:707.
62. Lehr HA, Mankoff DA, Corwin D, et al. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997;45:1559.
63. Grudzinski JJ, Burnette RR, Weichert JP, et al. Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape. Cancer Biother Radiopharm 2010;25:417.
64. Lorusso D, Di Stefano A, Carone V, et al. Pegylated liposo-mal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome). Ann Oncol 2007;18:1159.
65. Brush J, Lipnick SL, Phillips T, et al. Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol 2007;17:121.
66. Baechler S, Hobbs RF, Prideaux AR, et al. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys 2008;35:1123.
67. Grudzinski JJ, Tome W, Weichert JP, et al. The biological effectiveness oftargeted radionuclide therapy based ona whole-body pharmacokinetic model. Phys Med Biol 2010;55:5723.
68. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 2006;8:324.
69. Pereira JM, Stabin MG, Lima FR, et al. Image quantification for radiation dose calculations-limitations and uncertainties. Health Phys 2010;99:688.
70. Hasegawa BH, Wong KH, Iwata K, et al. Dual-modality imaging of cancer with SPECT/CT. Technol Cancer Res Treat 2002;1:449.